Details of the Drug-Related molecule(s) Interaction Atlas

BW 373U86 Drug Info

BW 373U86; BW-373U86; SNC-86; CHEMBL25230; 155836-50-3; BW373U86; 4-((R)-((2S,5R)-4-allyl-2,5-dimethylpiperazin-1-yl)(3-hydroxyphenyl)methyl)-N,N-diethylbenzamide; 4-[(R)-[(2S,5R)-2,5-dimethyl-4-prop-2-enylpiperazin-1-yl]-(3-hydroxyphenyl)methyl]-N,N-diethylbenzamide; LBLDMHBSVIVJPM-YZIHRLCOSA-N; 150428-54-9; Tocris-1663; AC1L3O2K; (+-)-4-((alpha-R*)-alpha-((2S*,5R*)-4-Allyl-2,5-dimethyl-1-piperazinyl)-3-hydroxybenzyl)-N,N-diethylbenzamide; SCHEMBL232127; GTPL9002; CHEBI:114187; MolPort-023-276-182

Cross-matching ID

PubChem CID

119029

ChEBI ID

CHEBI:114187

CAS Number

CAS 150428-54-9

TTD Drug ID

DMXFZWJ

General Information of Drug (ID: DMXFZWJ)

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Opioid receptor delta (OPRD1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Codeine	DMJX6ZG	Allergic rhinitis	CA08.0	Approved	[2]
Hydromorphone	DMHP21E	Back pain	ME84.Z	Approved	[3]
Loperamide	DMOJZQ9	Diarrhea	ME05.1	Approved	[4]
Eluxadoline	DMYZ0P1	Diarrhea-predominant irritable bowel syndrome	DD91.01	Approved	[5]
Oxycodone	DMXLKHV	Osteoarthritis	FA00-FA05	Approved	[6]
Butorphanol	DM5KYPJ	Pain	MG30-MG3Z	Approved	[2]
Carfentanil	DM7ADGX	N. A.	N. A.	Phase 2	[7]
Met-enkephalin	DMSZFTP	Pain	MG30-MG3Z	Phase 2	[8]
AZD-2327	DM8FZOG	Anxiety disorder	6B00-6B0Z	Phase 2	[9]
ADL-5747	DMMUPTN	Pain	MG30-MG3Z	Phase 2	[10]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Opioid receptor delta (OPRD1)	TT27RFC	OPRD_HUMAN	Agonist	[1]

------------------------------------------------------------------------------------

References

1	BW373U86, a delta opioid agonist, partially mediates delayed cardioprotection via a free radical mechanism that is independent of opioid receptor stimulation. J Mol Cell Cardiol. 2001 Aug;33(8):1455-65.
2	Butorphanol: effects of a prototypical agonist-antagonist analgesic on kappa-opioid receptors. J Pharmacol Sci. 2005 Jun;98(2):109-16.
3	Identification of opioid ligands possessing mixed micro agonist/delta antagonist activity among pyridomorphinans derived from naloxone, oxymorphone, and hydromorphone [correction of hydropmorphone]. J Med Chem. 2004 Mar 11;47(6):1400-12.
4	Loperamide: evidence of interaction with mu and delta opioid receptors. Life Sci. 1983;33 Suppl 1:315-8.
5	Molecular characterization of eluxadoline as a potential ligand targeting mu-delta opioid receptor heteromers.Biochem Pharmacol.2014 Dec 1;92(3):448-56.
6	Oxycodone: a pharmacological and clinical review. Clin Transl Oncol. 2007 May;9(5):298-307.
7	Wax PM, Becker CE, Curry SC: Unexpected gas casualties in Moscow: a medical toxicology perspective. Ann Emerg Med. 2003 May;41(5):700-5.
8	Delta-opioid receptor agonists inhibit neuromuscular transmission in human colon. Eur J Pharmacol. 1994 Sep 1;262(1-2):33-9.
9	Preclinical pharmacology of AZD2327: a highly selective agonist of the delta-opioid receptor. J Pharmacol Exp Ther. 2011 Jul;338(1):195-204.
10	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 317).